An interventional study of Team Alice Medication Safety and Empowerment Curriculum (MedSEC) in Older Adults, Medication and Supplement Use and Caregiver Awareness, sponsored by State University of New York at Buffalo. Recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by State University of New York at Buffalo · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Patient Participation with a site in United States — 27 open to participants now, 31 under way, none of them phase 3. Patient Participation · United States.
Among the 154 studies in Patient Participation with a site in United States, this one is the 72nd largest by planned enrollment of the 139 interventional ones that give a count, is one of 14 that started in 2026, is one of 132 with no phase, reaches primary completion later than 13 of the 30 other live ones, and was the 145th registered.
409 studies on the registry are indexed under Patient Participation; 100 are open to participants now.
Browse Patient Participation studies →27 of the 154 studies in Patient Participation with a site in United States are open now. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+ · Women only · Healthy volunteers
William Brandenburg, MD · Sites in United States
Ages 18+ · Healthy volunteers
University of Nebraska · Sites in United States
Ages 15–18
University of Washington · Sites in United States
Ages 14+ · Healthy volunteers
Columbia University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Patient Participation studies recruiting now, 32 (67%) set no upper age limit and 9 (19%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 2 · Phase 4 1
First in 2002; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is close to the median of 128 across 322 interventional studies indexed under Patient Participation.
Median enrollment 130 across the 139 interventional studies, 257 across the 15 observational. Of the 114 that completed or were terminated, 41 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 154 have an industry lead sponsor. The 10 most frequent:
State University of New York at Buffalo is the lead sponsor of 294 studies on the registry; 63 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
State University of New York at Buffalo has 2 studies filed under Patient Participation — fewer than ten, so there is no comparison to draw.
13 of the studies in Patient Participation with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989593Sarah SchlegelBreaking Silence Through Story: A Narrative Medicine Intervention for Parents of Children With Urogenital Conditions | 2026-11 |
| NCT06246409University of FloridaModernizing Instructions to Improve Treatment Participation of Subjects During Their First Radiotherapy | 2026-12 |
| NCT07489105Auburn UniversityForge AHEAD: Feasibility of Yoga to Improve Cognitive Function | 2026-12-31 |
| NCT06581484University of California, San FranciscoImproving Congenital Heart Disease Care | 2026-12-31 |
| NCT06358261Johns Hopkins UniversityStudy of a Diabetes Prevention Patient Activation Clinical Decision Support Tool | 2027-01-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 154 studies in Patient Participation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Team Alice's Medication Safety and Empowerment Curriculum (MedSEC) helps older adults and caregivers learn how to safely manage medications. Many seniors take multiple medications, which can lead to harmful side effects or unnecessary treatments. This program, developed at the University at Buffalo, will be offered at senior centers in Western New York. It includes two interactive sessions that teach participants how to recognize medication risks and talk with their doctors about safer options. The curriculum uses videos, group discussions, and hands-on tools to build confidence and knowledge. It follows the "4Ms" of Age-Friendly Health Systems: What Matters, Medication, Mentation, and Mobility. A "Train-the-Trainer" model will help senior center staff continue the program long-term. The goal is to reduce medication harm, improve communication with healthcare providers, and support healthy aging in the community.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Carepartner Inclusion Criteria:
Exclusion Criteria:
A two-part interactive curriculum that will improve medication safety awareness and empower participants to engage in conversations with healthcare providers. The focus of this study will be to evaluate the impact of the MedSEC on patient/care-partner knowledge and medication management patient activation levels. A pre/post study that surveys older adults/caregivers pre-curriculum intervention and post-curriculum intervention, in addition to 6 months after program completion.
Evaluate the impact of the MedSEC on patient/care-partner knowledge and activation levels in managing medications through the Patient Activation Measure (PAM)
Study seeks to enhance patient and care-partner activation, reduce polypharmacy and the use of potentially inappropriate medications (PIMs), and improve shared decision-making through the Patient Activation Measure (PAM).
Time frame: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
Evaluate the impact of the MedSEC on patient/care-partner knowledge and activation levels in managing medications through the Revised Patient Attitudes Towards Deprescribing (rPATD) questionnaires.
Study seeks to enhance patient and care-partner activation, reduce polypharmacy and the use of potentially inappropriate medications (PIMs), and improve shared decision-making through the Revised Patient Attitudes Towards Deprescirbing (rPATD) questionnaires.
Time frame: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
Change from Baseline in participant understanding of medication safety risks at 6 Months.
85% of participants will demonstrate an understanding of medication safety risks through pre- and post-program patient/caregiver questionnaires, including the Patient Activation Measure (PAM) and Revised Patient Attitudes to Deprescribing (rPATD). Additional questions pertaining to knowledge retention and actionability will be asked at 6 months.
Time frame: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
Participants will demonstrate knowledge of the 4Ms (Age-Friendly Health System) framework through pre/post/6 month follow up questionnaires.
By the end of the program, 80% of participants will demonstate knowledge of the 4Ms framework, measured by four questions related to the 4Ms and the Age-Friendly Health System taken prior to the program, immediately post-program, and 6 months after program completion.
Time frame: Change from baseline, post-program assessment (immediately after program completion), and 6 months after program completion.
Change in patient engagement as measured by the Patient Activation Measure (PAM) from baseline to 6 months post program.
6 months post-program, 65% of participants will show improved patient engagement, as measured by the Patient Activation Measure (PAM) questionnaire.
Time frame: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
Change from baseline in the mean of medications after 6 months follow-up
Within 6 months of completing program, 50% of participants with polypharmacy will have reduced medication usage by 10%. (mean # of medications.)
Time frame: Change from baseline and 6 months after program completion.
Post-Survey to Measure Program Impact and Participant Satisfaction
A post-survey questionnaire (immediately after program completion) will be used to assess the program's educational value and determine its effectiveness in increasing medication safety knowledge, empowerment, and patient self-advocacy, as well as participant satisfaction.
Time frame: Post curriculum session 2 (immediately after educational session 2, Day 7)
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.
Of 219 non-industry interventional studies with no phase under Patient Participation, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 12 months is below that.
Counting every sponsor, half of 226 studies reached it within 20 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
State University of New York at Buffalo →